Dr. John Cush RheumNow
3 years 3 months ago
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC
Dr. John Cush RheumNow
3 years 3 months ago
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform.
https://t.co/4c4oQwY9G6 https://t.co/iRa7wG5yOv
Dr. John Cush RheumNow
3 years 3 months ago
Watch: Zoster Management and Vaccination
Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy.
https://t.co/JcZNaeYuqh https://t.co/WF1PdlIbTO
Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!
Dr. John Cush RheumNow
3 years 3 months ago
Pegloticase Plus Methotrexate in Refractory Gout - MIRROR Study 12 mos. Results
The 12-month safety and efficacy of pegloticase + methotrexate (MTX) in the MIRROR trial shows continued efficacy and tophi resolution after 12 months of therapy.
https://t.co/8Jhy7gebMD https://t.co/ihZddj7b36
Dr. John Cush RheumNow
3 years 3 months ago
Biologics Keep Early RA in Check for at Least One Year
Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported.
https://t.co/FBFX53lZfp https://t.co/l1RapKWlFk
Dr. John Cush RheumNow
3 years 3 months ago
Metanalysis of 8 RCT, 188751 pts assessed mortality risk & FM. Overall, all-cause mortality increased in FM (HR 1.27, 1.04 to 1.51), but not in subgroup Dx by 1990 criteria. Increased SMR for accidents, infxn, suicide & decreased for cancer (0.82) https://t.co/Ujv8KP8FJK https://t.co/lNGUM0wB3O
Dr. John Cush RheumNow
3 years 3 months ago
ICYMI: RA Disease Activity and Alcohol Use
https://t.co/tXuAJ4GRl4 https://t.co/3ieVw8BcIs
Dr. John Cush RheumNow
3 years 3 months ago
35 SLE pts Rx w/ RTX x 3 ys-anti-RTX antibodies found @3 yrs in 64%, higher if previously RTX treated (vs naive). ADA+ had signif lower median RTX levels at 6 mos (P = 0.0018) and increased relapse rates. In vitro showed neutralizing capacity these Abs https://t.co/oV7nHxiS4s https://t.co/p55MvcLDFn
The oral Janus kinase 1 inhibitor filgotinib is available worldwide, but not in the USA, where the FDA held up its approval for use in RA due to unfinished studies of filgotinib's effects on sperm cells. The results of 2 phase two studies (MANTA and MANTA-RAy) confirm that filgotinib has no measurable impact on semen parameters or sex hormones in men with active IBD or inflammatory rheumatic diseases.
Monitoring for antidrug antibodies with biologic has not been routine in rheumatology but a new study suggests that antidrug antibodies correlate with nonresponse to bDMARDs in rheumatoid arthritis (RA) patients.
Dr. John Cush RheumNow
3 years 3 months ago
Metanalysis 62 RCTs & 16 LTE RCTs looks at neoplasia risk in JAKi, TNFi, MTX, PBO. Total CA rate=1.15/100PYs in RCTs. No diff in all CA between JAKi vs PBO or JAKi vs MTX (IRR 0.77); but JAKi had more CA than TNFi (1.50; 1.16, 1.94) https://t.co/aiJHQ5oPqt https://t.co/8MjJv728sh
Dr. John Cush RheumNow
3 years 3 months ago
RA Biologics Lower COVID-19 Deaths, but Not Recovery Time
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
https://t.co/o56m9WumiC. https://t.co/GHe1RprDnk
Dr. John Cush RheumNow
3 years 3 months ago
Baricitinib Effective in JIA Subsets
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
https://t.co/0CMzVCgsG8 https://t.co/NGE1pxsmcb
